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Background: The goals for the management of COPD are to delay the process of disease
progression and alleviate its manifestations. The follow-up of the patients’ physical and
mental condition is part of best practice management when monitoring routines results in
information that contributes to the achievement of management goals. However, the
recommendations on monitoring procedures may differ between guidelines and may not be
based on scientific evidence. The aim of this article is to review the current guideline
recommendations on monitoring routines for COPD.
Methods: Clinical practice guidelines on the management of COPD were identified by a
Medline search, Internet search and expanded by experts in the respiratory field.
Guidelines on the management of COPD were analysed on recommended monitoring
routines, recommended frequency of monitoring.
Results: Eighteen clinical practice guidelines on the management of COPD were
analysed. The follow-up of lung function indices was the most frequently recommendedElsevier Ltd. All rights reserved.
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L. van den Bemt et al.634monitoring routine. Moreover, monitoring of symptoms, exercise tolerance, comorbidity,
and smoking habits were recommended regularly. In none of the guidelines, the
recommended monitoring routines were evidence based. Only one guideline provides a
different set of monitoring parameters for advanced COPD compared to mild and
moderate COPD.
Conclusion: Some monitoring routines were recommended frequently, especially follow-
up of lung function indices. However, evidence to support the guideline recommendations
for the monitoring of patients with COPD is missing. The effect of monitoring on care
process and outcomes should be assessed.
& 2007 Elsevier Ltd. All rights reserved.Contents
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Chronic obstructive pulmonary disease (COPD) is a chronic
condition that, by definition, is not amenable to cure.
Therefore, the goals for the management of COPD are to
delay disease progression and alleviate its manifestations.1
Periodic assessments that guide the management of a
chronic or recurrent disease is usually called ‘monitoring’.2
The follow-up of the patients’ physical and mental
condition is part of best practice when this results in the
achievement of the management goals.3 Monitoring
should therefore be based on markers of disease progression
that truly predict outcome of disease and guide interven-
tions to improve outcome. This would require a scientific
evidence base of ‘monitored markers’.4 The latest revision
of the global strategy for the diagnosis, management,
and prevention of chronic obstructive pulmonary disease
(GOLD-guideline) includes a paragraph on monitor of
the disease.5 Moreover, over the past few years, several
other clinical practice guidelines (CPGs) on the management
of COPD have been published with directives on monitoring
the status and prognosis of COPD.6–8 The reality is, however,
that not all recommendations are evidence based and
that most CPGs contain additional ‘opinion-based’ recom-
mendations. We previously reflected on monitoring
routines as currently recommended in clinical COPD guide-
lines, and how opinion-based recommendations may not
necessarily result in clinical benefits or even cause an
unnecessary physical or mental burden for patients,
and an economic burden for the society at large.9 An
overview of guideline recommendations regarding monitor-
ing COPD patients is currently lacking. In this article, wereview current COPD guidelines’ recommendations on
monitoring routines, the recommended frequency of the
monitoring visits, and the level of scientific evidence of the
recommendations.Methods
To identify CPGs on the management of COPD, a Medline
search was carried out using the terms ‘COPD’ (exploded)
and ‘guideline’. The treatment guideline links on the
Pubmed site were searched on CPGs on the management
of COPD (for instance, www.nelh.nhs.uk, and National
Guideline Clearinghouse). Moreover, an Internet search
engine (GoogleTM) was used to search for additional CPGs.
Finally, experts in the field of COPD disease management
were asked to complete the list of guidelines. Only CPGs
that addressed the integral management of COPD from
diagnose on to treatment and (terminal) care were selected.
CPGs for specific subgroups of patients or restricted to a
specific aspect were not selected. The search was restricted
to CPGs written in English or Dutch language that had been
published or updated after the year 2000 and were still
accurate at the time of our analysis. Table 1 shows the
characteristics of the selected CPGs, including the title, the
year of the latest update, and the organisation responsible
for its development. More information on the CPGs (e.g. its
clinical goal, definition of COPD, the professional groups
included in development and target users) is described in an
online data supplement (see online data supplement).
Monitoring of chronic disease was defined as the process
of periodically assessing, observing, recording and/or
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Table 1 Description of the characteristics of the selected clinical practice guidelines for chronic obstructive pulmonary
disease.
Abbrevia-
tion
Organisation Year Country/
region
Title in English Evidence
grading (EG)
EG
monitoring
GOLD Collaboration of many
organisations including
American Thoracic
Society, European
Respiratory Society, and
World Health
Organisation
2006 Global Global strategy for the
diagnosis, management,
and prevention of
chronic obstructive
pulmonary disease
+ 
ATS/ERS American Thoracic
Society and European
Respiratory Society
2004 Global Standards for the
diagnosis and treatment
of patients with chronic
obstructive pulmonary
disease
 
IPAG International Primary
care Airway Group
2004 Global Chronic airway diseases;
a guide for primary care
physicians
 
IPCRGy International Primary
Care Respiratory Group
2006 Global International Primary
Care Respiratory Group
(IPCRG) Guidelines:
management of chronic
obstructive pulmonary
disease (COPD)
+ +
EBM Duodecim medical
publications Ltd.
2004 Global Evidence-based
medicine guideline;
chronic obstructive
pulmonary disease
+ 
COPD-X The Thorax Society for
Australia and New
Zealand and the
Australian Lung
Foundation
2007 Australia/
New
Zealand
Chronic obstructive
pulmonary disease
(COPD) Australian and
New Zealand
management guidelines
and the COPD handbook
(COPD-X)
+ 
CTS Canadian Thoracic
Society
2004 Canada Canadian Thoracic
Society
recommendations for
the management of
chronic obstructive
pulmonary disease
+ 
BCMA British Columbia Medical
Association
2007 Canada Chronic obstructive
pulmonary disease
(COPD)
 
India WHO (India) 2003 India Guidelines for
management of chronic
obstructive pulmonary
disease (COPD) in India:
a guide for physicians
 
CBO Collaboration of many
organisations including
Dutch College of
General Practitioners
and Dutch Institute for
Health Care (CBO)
2005 Netherlands Guideline integrated
care COPD
+ +
NHG Dutch College of
General Practitioners
2007 Netherlands NHG-standard COPD  
PA Palestinian Ministry of
Health
2003 Palestian
region
Palestinian guideline for
diagnosis and
 
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Table 1 (continued )
Abbrevia-
tion
Organisation Year Country/
region
Title in English Evidence
grading (EG)
EG
monitoring
management of chronic
obstructive pulmonary
disease
SA South African Thoracic
Society
2004 South-
Africa
Guideline for the
management of chronic
obstructive pulmonary
disease (COPD)
 
SRS Swiss Respiratory
Society
2002 Swiss Management of chronic
obstructive pulmonary
disease: the Swiss
guidelines
+ 
CKS National Health Service
and Department of
Health United Kingdom
(UK)
2007 UK Clinical knowledge
summaries (converted
from prodigy guidance)
chronic obstructive
pulmonary disease
+ +
NICE National Collaborating
Centre for Chronic
Conditions
2004 UK Chronic obstructive
pulmonary disease.
National clinical
guideline on
management of chronic
obstructive pulmonary
disease in adults in
primary and secondary
care
+ 
ISCI Institute for Clinical
System Improvement
United States of America
(USA)
2007 USA Health care guideline;
chronic obstructive
pulmonary disease
+ 
ABFP American Board of
Family Practice
2001 USA Reference guide COPD  
Either the year of initial publication or, in case of periodic update of the guideline, the year of the most recent update.
yIPCRG and IPAG guideline are developed by the same group of experts.
L. van den Bemt et al.636testing of certain aspects of a patient’s physical and mental
condition.10 Consequently, all recommendations on periodic
collection of data about the physical and/or mental
condition of patients were listed as ‘monitoring routines’.
General recommendations regarding monitoring of COPD
patients were searched, like whether or not an hierarchic
evidence grading system had been applied for the
recommendations in the CPGs, if the monitoring recommen-
dations were actually evidence graded, and whether
or not there is a separate paragraph on monitoring included
in the CPG. Moreover, the full text of each CPGs was
analysed to identify all aspects that should be monitored or
be part of follow-up visits of patients by one of the authors
(LB) and independently verified by a second author (TS).
Next, the search function in the text processing program
was used to crosscheck for terms like monitor*, follow-up
and audit* (or Dutch equivalents when applicable) in the
CPGs. All monitoring routines recommended by the CPGs
are given in Table 2. The monitoring routines that were
recommended by more than a third of the CPGs (nX7)are described in Table 3. Monitoring routines that were
implied but not specifically recommended were graded
with a +/ sign.Results
Clinical practice guidelines on the management
of COPD
Nineteen CPGs on the management of COPD were identified
that had been published or updated after the year 2000 and
fulfilled the other inclusion criteria. One CPG was excluded
because it only consisted of three written pages with no
literature references.11 The remaining 18 CPGs were
screened regarding the recommended monitoring routines.
Characteristics of the CPGs are given in Table 1 and the
online data supplement. One CPG did not give any
recommendations regarding monitoring routines.12 Twelve
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Table 2 Monitoring routines recommended by one or
more of the selected clinical practice guidelines for
chronic obstructive pulmonary disease (COPD).
Monitoring routines Number of
guidelines
(n ¼ 18)
Lung function 16
Symptoms/dyspnoea 15
Smoking habits 13
Exercise tolerance 11
Comorbidity/complications 11
Exacerbations 11
Inhaler technique 9
Side effects of treatment 8
Effect of drug treatment 8
Nutritional condition 8
Compliance with treatment 8
Theophylline levels in blood if prescribed 6
Quality of life/health status 6
Arterial blood gasses 5
Hospital admissions 4
Symptoms control 4
Physical examination 3
Psychosocial disorder/depression 3
Limitations caused by COPD 2
Need for adjustments in work situation 2
Need for long-term oxygen therapy (LTOT) 2
Health care need 1
Need for referral to lung physician 1
Need for pulmonary rehabilitation 1
Need for other therapies 1
Guidelines’ recommendations on monitoring COPD 637CPGs (67%) included a separate paragraph on monitoring
disease or follow-up visits.5–8,13–20Recommended monitoring routines
Sixteen of the CPGs (89%) recommended monitoring of lung
function (Table 2). When a definition of lung function
monitoring was given in the guidelines, it was always the
spirometric measurement of the (change in) FEV1 (forced
expiratory volume in 1 second), sometimes combined with a
recollection of information on the FEV1/FVC ratio. Monitor-
ing of symptoms, exercise tolerance, comorbidity, exacer-
bations, inhaler technique, and smoking habits were
recommended by at least half of the CPGs. There was large
agreement on recommended monitoring routines between
the NICE, CBO, GOLD, CKS, COPD-X, ABFP, and NHG
guidelines.5–7,15,16,18,20 Additionally, the ATS/ERS standards
for the diagnosis and management of patients with COPD
recommend that the ‘‘intensity’’ of follow-up visits should
be based on the patient’s disease status and course, though
without providing specific recommendations.8 The NICE
guideline is the only guideline that recommends a different
set of monitoring routines for patients with mild or
moderate COPD compared to patients with severe disease.6For example, nutritional state and oxygen saturation should
only be monitored in patients with severe COPD.6
Frequency of monitoring visits
Six CPGs (33%) did not provide any information on the
frequency of follow-up visits;13,15,21–26 three CPGs (17%)
indicate that the frequency of monitoring visits should
depend on the local health care system;5,8,14 and nine CPGs
(50%) recommend that the number of visits should be tuned
to the disease severity and progression of the individual
patient.5–8,14,16,17,19,20 Eight CPGs provide suggestions for
the frequency of monitoring visits that vary between
monthly to yearly.5–7,16–20 Moreover, one CPG (CBO) recom-
mended monitoring of lung function in a lower frequency
than other monitoring routines, i.e. once every three years.7
Evidence grading monitoring recommendations
Nine CPGs (50%) provided information regarding the
level of evidence for management recommenda-
tions.5–7,12,14,15,19,21,22,26 Usually the evidence was graded
from the highest level of evidence: A (evidence resulted
from several well-designed randomised clinical trials) till
the lowest level of evidence: D (expert opinion).27 Only
three CPGs—the CBO, IPCRG and NICE guidelines—used an
evidence grading system for some of their specific monitor-
ing recommendations.6,7,14 According to these guidelines,
there was no scientific evidence for any of the monitoring
recommendations (i.e. all monitoring recommendations
were based on expert opinion).
Discussion
This review identified 19 CPGs on the management of COPD
of which 18 were analysed on recommendations concerning
disease monitoring in patients with COPD and the evidence
behind these recommendations. The follow-up of lung
function was the most frequently recommended monitoring
routine. Symptoms, smoking habits, exercise tolerance, and
comorbidity were also frequently recommended. However,
none of the guidelines provided scientific evidence for their
recommended monitoring routines. This implies that there is
scant evidence that the defined ‘best practice’, is in the
best interest of the patients with COPD. In appraising our
findings, more emphasis should be placed on the nature of
the information to be monitored. None of the guidelines we
reviewed made the distinction between ‘direct’ monitoring
of outcome of care—for example, symptom relief, or
smoking cessation—and the monitoring that predicts the
prognosis and of long-term outcome of care. As discussed
elsewhere, measuring the direct outcome of care is usually
self-evident, but monitoring the long-term course is based
on markers of disease progression (pulmonary function; body
mass index (BMI)) and in this evidence of its predictive value
and therapeutic implications are essential.9 Some monitor-
ing procedures like monitoring dyspnoea can serve several
goals (i.e. facilitate COPD management decision making
and provide information on disease progression). Below,
we review the nature of the recommended monitoring
procedures based on literature.
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Table 3 Recommendations on monitoring routines by clinical practice guidelines for chronic obstructive pulmonary disease
(COPD).
Monitoring parameters NICE CBO IPCRG GOLD EBM CKS ICSI CTS COPD-X
Lung function + + + +  + + + +
Symptoms/dyspnoea + + + +  +  + +
Smoking habits + + +/ +  + + +/ +
Exercise tolerance + + +/      
Comorbidity/complications + + +/ +  + +  +
Exacerbations + + +/ +  +   +
Inhaler technique + +  +  +   +
Side effects treatment + + + +     +
Effect of drug treatment + +  +  + +  +
Nutritional condition + +    +   +
Compliance with treatment  + + +  +   +
Monitoring
parameters
SRS ATS/
ERS
IPAG ABFP NHG BCMA India SA PA Number of
guidelines
Lung function  + +/ + + + +/ + + 16
Symptoms/
dyspnoea
+/ + +/ + +  +/ +/ + 15
Smoking habits  +  + +  +/  + 13
Exercise tolerance +/ + +/ + +   +/ + 11
Comorbidity/
complications
 +  + +  +/   11
Exacerbations  +/  + + + +/   11
Inhaler technique    + +   +  9
Side effects
treatment
   + +    + 8
Effect of drug
treatment
   + +     8
Nutritional
condition
 +  + +   +/  8
Compliance with
treatment
   + +    + 8
Scoring legend monitoring routines: +, monitoring routine recommended in CPG; +/, item was mentioned in CPG, but unclear for
reviewers if it was meant to be a monitoring procedure; , monitoring routine not mentioned in CPG.
L. van den Bemt et al.638Smoking cessation is the only intervention that could
reduce the lung function decline of patients with COPD.28
Smoking cessation also relieves symptoms and reduces
mortality.29 Though difficult to achieve, there are opportu-
nities to improve the success rate of smoking cessation.30
Therefore, monitoring of smoking status is important to
identify smoking cessation opportunities, thereby improving
disease status in short term (i.e. ‘direct’ monitoring) and
delay disease progression.
Also, identifying symptoms is important to direct therapy.
Symptoms are the patients’ subjective perception of disease
manifestation and symptom relieve should have a prominent
place in the management of COPD.5 Pharmacological
therapy, smoking cessation, and pulmonary rehabilitation
can reduce symptoms.31–33
Moreover, various interventions can reduce the number of
(hospitalised) exacerbations; use of inhaled corticosteroids,
the use of a long acting bronchodilators, and self-manage-
ment.34–37 Exacerbations impairs quality of life and causefrequent hospital admissions and increased health care
costs, especially in patients with more severe COPD.38–40
Early introduction of treatment for exacerbations resulted
in faster recovery of the exacerbation.41 Therefore, the
evaluation of the pattern of exacerbations as a part of
periodic monitoring could lead to improved care.
Next, using medication in an appropriate way seems
essential to have optimal benefits of treatment with
minimal side effects of therapy (i.e. monitoring inhaler
technique, effect and side effects of drug treatment).
For example, most COPD medication is delivered by
inhalers, which reduces systematic side effects, but
about a quarter of patients with COPD make at least one
essential mistake when using their inhaler device.42 Good
inhaler technique has been related to symptom relieve,
improve quality of life, reduce exacerbations, and improve
exercise tolerance.31,35 Instructions and educational pro-
grams can improve the inhaler technique of patients with
COPD.43,44
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Guidelines’ recommendations on monitoring COPD 639Moreover, patients with COPD frequently suffer from
comorbid conditions and complications. Over 20% of COPD
patients in a primary care population had undiagnosed
congestive heart failure.45 Identifying comorbidity and
complications could lead to (early) treatment and improved
disease course or disease state by timely initiation of
interventions that are not directly related to COPD (e.g.
treatment of heart failure with diuretics, vasodilator
therapy, and treatment with inotropic agents).
Finally, exercise capacity, often assessed by establishing
the 6min walking distance (6MWD), is influenced by lung
capacity but also by extrapulmonary effects of COPD like
diminished skeletal muscle strength.46 Research on the
effectiveness of pulmonary rehabilitation has shown im-
provements on various outcomes, like the exercise capacity
test, quality of life, prognosis, and incidence of comorbid-
ity.47 Monitoring exercise tolerance could be useful to
identify the patients that could benefit most from this
intervention.
In addition to dyspnoea, lung function and exercise
tolerance, the BMI may predict survival in patients with
COPD (i.e. prognostic monitoring).48 Involuntary weight lost
is associated with increased dyspnoea, impaired quality of
life and less exercise tolerance in severe COPD.49,50 The
effect of caloric supplementation on different outcomes like
anthropometrical measures and exercise capacity in pa-
tients with stable COPD was found to be small and
insignificant in a recent meta-analyses of published stu-
dies.51 So no clear statement can be made on the value of
monitoring BMI in case of COPD.
What is more, the most frequently recommended mon-
itoring routine—lung function (i.e. assess FEV1 change)—has
primarily an informative character, without therapeutic
implication since no present therapy other than smoking
cessation was found to modify the lung function decline
in patients with COPD. However, spirometric testing remains
essential to diagnose COPD and provides information on
an important aspect of disease severity and progression.48
As the disease progresses, periodic reassessment of
the severity of airflow obstruction enables the selection
of stage-specific treatment recommendations, like the
treatment with an inhaled steroid to prevent exacerbations,
which is only recommended for patients with a FEV1
below 50% of the predicted value.52 Moreover, a small
improvement on lung function status was found
when interventions were introduced, like the use of
bronchodilators.31
Only two-third of the CPGs included a specific paragraph
on monitoring COPD. The majority of CPGs that comprise
recommendations on monitoring frequency recommend
that the number of visits should be tuned to the severity
and course of disease of each particular patient. In contrast
to the number of monitoring visits, CPGs recommendations
regarding monitoring routines did not differ between
patients with different stages of disease severity, except
in the NICE guideline.6 Several routines may not be
applicable to the patients with mild or moderate COPD,
like the monitoring of arterial oxygen saturation, whereas
these patients make out the vast majority of the COPD
patient population.53 Moreover, it is remarkable to see that
the recommended frequency of performing does usually not
differ between the recommended routines, despite the factthat there are important differences in the relevance of
the acquired information, costs of the routines/measure-
ments, and their burden for the patients. Although good
follow-up is essential to achieve the optimal level of COPD
patient care, the attention paid to monitoring in most
CPGs is limited. To a certain extent this may be the result
of the complete lack of well-designed studies on this
topic, especially in contrast to other areas of COPD disease
management like, for instance, pharmacotherapy. We
suggest that studies on monitoring of COPD should
focus on those routines that are not self-evident and
result in considerable burden for the patient and/or
society. For instance, evidence should be collected on the
value of regular lung function monitoring and the effect of
monitoring the exercise tolerance in patients with mild to
moderate COPD. The effectiveness of these monitoring
routines should be evaluated on clinical benefits for the
patients like a reduction of symptoms, and improvement of
quality of life.
Some methodological considerations warrant mentioning.
This overview was limited to CPGs written in Dutch and
English and consequently do not provides an overview of all
guidelines developed worldwide. What is more, since CPGs
are updated regularly and new scientific evidence becomes
available continuously, the results in this article must be
seen as a ‘freeze-frame’. Next, it was not always clear
whether or not the procedure was a monitoring routine in
the eyes of the authors of the CPGs. On the other hand, it
might be that monitoring routines cannot be recognised as
such, because of the formulation in the CPG. For example,
all CPGs emphasised smoking cessation, with the recom-
mendation to inquire after the patients smoking status.
However, the subsequent periodic review of smoking status
was not always recommended.
In this study, we focussed on the monitoring recommen-
dations in the CPGs. Therefore, the quality of the whole
CPGs was not assessed according to the AGREE procedure.54
The essential information on the CPGs, including the
evidence grading system, was described in the online data
supplement.
In conclusion, gathering information on some of the
recommended monitoring parameters, like smoking status,
symptoms, and inhaler technique may serve an obvious
treatment purpose. At this time, insufficient information is
available to assure that the collection of this data results in
better management of patients with COPD. Therefore, it is
not possible to formulate conclusive advices on the
usefulness or benefits of guideline recommended monitoring
routines for patients with COPD. An evidence-based
approach on monitoring of patients with COPD seems
essential in order to provide and maintain the best possible
evidence based and efficient care. Moreover, evidence-
based monitoring recommendations—not only the fre-
quency but also the selected monitoring routines—should
preferably be tuned to the disease severity level of the
patient.Conflict of interest
No conflict of interest for any of the authors.
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